Targeting medulloblastoma: small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics.
Medulloblastoma is the most common malignant pediatric brain tumor for which no satisfactory treatments exist. The Sonic Hedgehog signaling pathway seems to play an important role in the pathology of this disease. Here we review our recent demonstration that a small-molecule inhibitor of this pathway can regress tumors that arise in a transgenic mouse model of medulloblastoma. These and other findings suggest that inhibitors of Sonic Hedgehog signaling may offer an effective way to target some malignancies.
Romer
Justyna
J
Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA. stysia.romer@stjude.org
Curran
Tom
T
D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001932:Brain Neoplasms / Q000188:drug therapy*; D004195:Disease Models, Animal; D053823:Hedgehog Proteins; D006801:Humans; D008527:Medulloblastoma / Q000188:drug therapy*; D051379:Mice; D008822:Mice, Transgenic; D015398:Signal Transduction / Q000187:drug effects; D015534:Trans-Activators / Q000037:antagonists & inhibitors* / Q000502:physiology
D001562:Benzimidazoles; D053823:Hedgehog Proteins; C509239:SHH protein, human; D015534:Trans-Activators